FOLD №7 — Structural Characterization of TB-500 (Ac-LKKTETQ) at the G-Actin Interface

Verdict: REFINED | Peptide: Ac-LKKTETQ | Target: Beta-actin (P60709) | Class: Regenerative

⚠️ Critical Reframe: The literature agent established that TB-500 as commercially formulated is already Ac-LKKTETQ. The acetyl cap is not a novel modification but the molecule's defining chemical identity. This fold therefore characterizes the native compound in complex with its target — a structurally informative baseline prediction with no prior computational precedent in the literature.

Mechanism of Action

Thymosin β4 (Tβ4) sequesters G-actin monomers to regulate the cytoskeletal equilibrium between filamentous (F-actin) and globular (G-actin) pools. The full 43-residue protein binds G-actin with low-nanomolar affinity; the heptapeptide TB-500 (Ac-LKKTETQ) corresponds to residues 17–23 and encodes the WH2 (WASP-homology 2) actin-binding motif responsible for the majority of this interaction. The N-terminal leucine inserts into a hydrophobic groove between actin subdomains 1 and 3, while the lysine residues at positions 2 and 3 make electrostatic contacts with the actin surface.

Actin sequestration downstream of TB-500 promotes cell migration, wound healing, angiogenesis, and cardiomyocyte survival — effects documented in preclinical models of tissue injury. The peptide also engages integrin-linked kinase (ILK) and PINCH signaling pathways, contributing to its broader regenerative pharmacology beyond direct actin dynamics.

Performance Applications

TB-500 is used in performance and recovery contexts primarily for its tissue-repair properties: acceleration of wound and tendon healing, attenuation of fibrosis, promotion of neovascularization, and potential cardioprotection following ischemic insult. The peptide is on the World Anti-Doping Agency (WADA) prohibited list, reflecting recognition of its performance-relevant biology. All established efficacy data are preclinical; no human randomized controlled trials have been published. This fold's computational characterization is relevant to understanding the structural basis of these activities at the actin interface.

Modification Rationale

The original hypothesis proposed N-terminal acetylation of TB-500 to confer aminopeptidase resistance and helix-nucleation stability. The literature finding that TB-500 already carries this modification reframes the rationale: the decision to acetylate was made at the level of compound design, and the metabolic evidence confirms it works as intended. Rahaman et al. (2024) found that all circulating metabolites in rats retained the Ac- group (Ac-LKK, Ac-LK), with no detection of unacetylated LKKTETQ, consistent with successful N-terminal protection. Degradation proceeds from the C-terminus, not the N-terminus — validating the acetylation strategy while identifying C-terminal stability as the remaining vulnerability.

The mechanistic rationale for acetylation-driven helix stabilization remains scientifically valid: neutralizing the free N-terminal amine removes electrostatic repulsion with the helix macrodipole, lowering the energetic cost of helix initiation. This is well-established in peptide biophysics, though it has not been directly measured for LKKTETQ specifically.

Predicted Properties (Favourable Relative to Unacetylated LKKTETQ)

The predicted complex shows an extended-to-helical backbone engaging the canonical LKKTET groove on G-actin. The N-terminal acetyl cap is accommodated without geometric distortion of the core pharmacophore. The pLDDT of 0.867 places this prediction in confident territory for a heptapeptide, and the ipTM of 0.817 indicates a well-constrained binding pose — metrics that establish a meaningful computational reference point.

Note on heuristic properties: Half-life, stability score, and aggregation propensity are sequence-based heuristic estimates, not experimental measurements. They should be treated as directional indicators only.

Suggested Next Steps

Immediate computational priorities:

1. Paired prediction of unacetylated LKKTETQ vs. Ac-LKKTETQ — Run both sequences under identical Chai-1 conditions to generate direct comparative pLDDT and ipTM values. This would be the first published computational comparison of the two forms and would directly test the helix-stabilization hypothesis. This is the single highest-value next step from this fold.

2. C-terminal amidation variant (Ac-LKKTETQ-NH₂) — Given that metabolic degradation proceeds C-terminally (generating Ac-LKK and Ac-LK), C-terminal amidation is the logical complementary modification to the existing N-terminal acetylation. A paired fold would predict whether this prolongs the intact pharmacophore in silico and would address the half-life vulnerability identified by Rahaman et al.

3. Extension variants — Predict Ac-LKKTETQ extended by 1–3 residues toward the native Tβ4 sequence (residues 24–26: ELE) to assess whether a slightly longer fragment improves interface geometry or stability scores without losing the compact binding mode.

Wet-lab validation priorities:

4. G-actin binding affinity comparison (SPR or ITC) — Measure Kd of Ac-LKKTETQ vs. LKKTETQ for purified G-actin. This is knowledge gap #3 from the literature review and has not been published.

5. Aminopeptidase resistance assay — Incubate Ac-LKKTETQ and LKKTETQ with purified aminopeptidase N and monitor by LC-MS/MS to formally quantify the protective effect of the acetyl cap, dissecting it from C-terminal exopeptidase activity.

6. NMR helical propensity measurement — CD or 2D NMR comparison of both peptide forms in aqueous solution would provide direct structural validation of the helix-stabilization hypothesis.

This fold establishes the first computational structural reference for TB-500 (Ac-LKKTETQ) at the G-actin interface. No prior AlphaFold or equivalent modeling study of this peptide:target complex was identified in the literature search (n=8 papers reviewed).